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ABSTRACT
Aims: The Impella is a percutaneous
ventricular assist device. The majority of
published data describes the 2.5L and 5.0L
devices, and little data is available for the
newer 3.8L device. We examined the
indications and outcomes from our
single-centre ‘‘real-world’’ registry at The
Queen Elizabeth Hospital, Birmingham, UK,
using all three pump sizes.
Methods and Results: Records from all patients
who underwent attempted Impella-assisted
procedures at our centre were examined
retrospectively. Impella implantation was
attempted in 49 patients (mean age
72 ± 13 years; 80% male) and was successful in
48 (98%). 45 patients underwent high-risk
percutaneous coronary intervention (PCI), one
patient underwent balloon aortic valvuloplasty
and 3 patients had Impella as a bridge to cardiac
transplantation. The 2.5L and 3.8L devices were
used in 36 (75%) and 11 (23%) patients,
respectively, while one patient (2%) had the
5L device. Vascular complications occurred in
only one patient (2%) and stroke and peri-
procedural myocardial infarction occurred in
one patient (2%), while in-hospital mortality
was 20% (10/49).
Conclusions: In this large real-world registry,
we have demonstrated the safety and feasibility
of the Impella device for a wide range of
indications. This includes the first series of the
3.8L device which provides superior support
with no increase in vascular complications.
Keywords: High-risk PCI; Impella 3.8L; Impella
device; Outcomes; Percutaneous coronary
intervention; Vascular complications
INTRODUCTION
Due to an ageing population, percutaneous
coronary intervention (PCI) is being
increasingly undertaken in patients with
multiple comorbidities and complex lesions.
As a result, PCI is increasingly performed in
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patients considered to be at prohibitive risk for
coronary artery bypass grafting (CABG) [1, 2].
Many of these patients also have significant left
ventricular (LV) impairment, and PCI in this
setting is associated with an increased risk of
peri-procedural complications [3, 4].
Mechanical-assist devices have been frequently
employed to support high-risk PCI in these
situations in the hope of reducing this risk.
Such mechanical assistance has been
conventionally provided by intra-aortic
balloon counterpulsation (IABP), although
randomised trials have failed to show benefit
of elective IABP both in high-risk PCI [5] and
cardiogenic shock complicating acute
myocardial infarction [6]. This may be due to
the limited support that counter-pulsation
provides in augmenting cardiac output and in
reducing left ventricular afterload.
Percutaneous left ventricular assist devices
(LVAD) such as the TandemHeart (Cardiac
Assist Inc., Pittsburg, USA) have been shown to
be safe and feasible in this setting, and also
provide superior haemodynamic support as
compared to IABP [7, 8]. However, the
TandemHeart is complex to use and requires
a trans-septal puncture.
The Impella (Abiomed, Danvers, USA)
device is a percutaneous catheter-based
impeller-driven LVAD which aspirates blood
from the LV cavity expelling the removed
blood into the aorta. It has been shown to
provide superior cardiac support compared with
IABP in both animal [9, 10] and human studies
[11], reducing LV end diastolic pressure, wall
stress, myocardial oxygen consumption and
improving coronary perfusion and cardiac
output [12–14].
The Impella device has gained increasing
popularity in acute cardiac care, most
commonly in high-risk PCI. Large registries
like USpella [1] and Europella [15] have
demonstrated the feasibility and safety of this
device in this setting. More recently, the
PROTECT-II trial is the first randomised
controlled trial demonstrating the
haemodynamic benefit of this device over
IABP in elective patients undergoing high-risk
PCI and a trend to improved clinical outcomes
at 30 days [16]. In addition to high-risk PCI,
Impella has also been used successfully in
cardiogenic shock [17–20], acute cardiac
transplant rejection [21, 22] and refractory
heart failure as a bridge to transplantation
[23, 24].
Historically, IABP has been the mechanical
assist device of choice in the UK, although
recent trials from the UK have shown no early
benefit of prophylactic IABP in elective high-
risk PCI [5], with a recent analysis showing a
beneficial effect on 5-year mortality [25]. We
therefore, present our experience with the use
of the Impella device in a UK quaternary cardiac
centre.
METHODS
The Queen Elizabeth Hospital, Birmingham,
UK, is a large quaternary cardiac centre and
provides regional cardiac transplantation. We
retrospectively analysed our interventional
procedural database and identified all patients
undergoing Impella implantation since the start
of the programme in October 2008 until
January 2014 on an intention to treat basis.
Clinical and procedural data was procured from
electronic patient records, the procedural
database and procedure logs in the cardiac
catheter laboratory. All patients were included
in an intention to treat manner; there were no
exclusions.
The 2.5L and 3.8L Impella devices were
inserted via the femoral approach. The 5L
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Impella was inserted via the subclavian artery
following surgical exposure and application of a
Dacron graft, as previously described [26]. For
trans-femoral access, arterial puncture was
performed after fluoroscopic localisation of the
femoral head, with or without ultrasound
guidance and, more recently, with the use of a
4F (French) micropuncture kit (Micropuncture
Introducer Set SilhouetteTM Transitionless,
Cook Medical Inc., USA) to minimise vascular
complications. A femoral angiogram was then
performed to ensure adequate vessel calibre
([4 mm) and to assess tortuosity and
calcification. Pre-closure was achieved using
two sutures (Perclose ProGlide 6F Suture-
Mediated Closure (SMC) System, Abbott
Vascular, Illinois, USA) following which a 13F
or 14F sheath was inserted for the 2.5L and 3.8L
devices, respectively.
A Judkins right or Amplatz catheter was used
to cross the aortic valve following which the
0.01800 Impella guide wire was positioned in the
aortic apex. The Impella device was then
positioned carefully in the LV apex over the
0.01800 wire and set to maximal output. Special
manoeuvres were required for insertion of the
device in the five patients who had
concomitant severe aortic stenosis (AS), as
described recently by our group [27].
Outcome data for mortality was obtained
from electronic patient records linked to the
Office of National Statistics database. Peri-
procedural myocardial infarction (PMI) was
defined as a total creatinine kinase level
greater than three times the upper limit of
normal on the morning after the procedure [28,
29]. Data are presented as mean ± standard
deviation (SD) for continuous variables and
percentages for discrete variables.
The analysis in this article is based on
previously conducted data, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Impella implantation was attempted in a total
of 49 patients during the study period: of these,
45 patients underwent high-risk PCI, 3 patients
required emergency haemodynamic support as
a bridge to cardiac transplantation and one
patient with severe AS underwent balloon
valvuloplasty (BAV) with Impella support.
Implantation of a 2.5L Impella failed in one
patient undergoing high-risk PCI due to
extreme calcific iliofemoral disease.
Implantation was successful in 48 (98%)
patients. Of these, the 2.5L Impella device was
used in 36 (75%) patients, the 3.8L device in 11
(23%) patients, and the 5L device in one patient
(2%).
The baseline clinical characteristics of these
patients are shown in Table 1.
High Risk PCI
45 patients, including five patients with
concomitant severe AS, underwent high-risk
PCI. Impella was successfully implanted in all
but one patient (44/45 [98%]). Of these, 10
patients were given the 13F 3.8L device, while
34 patients were given the 12F 2.5L device.
Impella was removed following PCI before the
patient left the catheter laboratory in all but two
patients and in these patients, successful
vascular closure was achieved with pre-closure
use of one or two ProGlide devices. PCI was
performed via the radial approach in 11 patients
(25%) and the femoral approach in 33 (75%).
The peri-procedural variables are shown in
Table 2.
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The majority of patients (80%) had severe LV
impairment (LVEF \35%) with 53% (24/45) of
patients undergoing PCI to an unprotected left
main stem. Five patients had severe AS with
coronary artery disease and PCI was performed
in preparation for transcatheter aortic valve
replacement (TAVR) or balloon valvuloplasty
for clinical stabilisation.
PCI was performed electively in 17 (38%)
patients: 11 of these patients were discussed at a
heart multi-disciplinary team (MDT) meeting
and were thought to be at higher risk for CABG.
Table 1 Baseline characteristics
Clinical characteristics Total High-risk PCI BAV Bridge to transplant
N5 49 N5 45 N5 1 N5 3
Age (years) (mean*) 72 ± 13 (37–92) 74 ± 11 (47–92) 67 48 ± 11(37–63)
Male 39 (80%) 35 (78%) 1 3 (100%)
BMI (kg/m2) (meana) 27 ± 4 (18–40) 27 ± 4 (20–40) 25 22 ± 3 (18–24)
Hypertension 40 (82%) 37 (82%) 0 3 (100%)
Diabetes 17 (35%) 16 (36%) 0 1 (33%)
Smoking 28 (57%) 26 (58%) 0 2 (66%)
Dyslipidemia 32 (65%) 31 (69%) 0 1 (33%)
Renal function
eGFR (ml/min) (meana) 51 ± 6 (11–117) 54 ± 27(16–117) 43 15 ± 4 (11–20)
eGFR 30–60 22 (45%) 21 (47%) 1 3 (100%)
eGFR\30 12 (30%) 9 (14%) 0 3 (100%)
PVD 4 (8%) 4 (9%) 0 0
CVD 3 (6%) 3 (7%) 0 0
Previous MI 24 (49%) 22 (49%) 0 2 (67%)
Previous CABG 3 (6%) 3 (7%) 0 0
Previous PCI 9 (18%) 7 (16%) 0 2 (67%)
LVEF\35% 39 (80%) 36 (80%) 1 3 (100%)
LVEF (%) (meana) 28 ± 14 (10–60) 28 ± 14 (10–60) 10 15 ± 4 (10–20)
Impella characteristics
Successful implant 48 (98%) 44 (98%) 1 3 (100%)
2.5L Device 36 (76%) 34 (77%) 0 2 (67%)
3.8L Device 11 (23%) 10 (23%) 1 0
5.0L Device 1 (2%) 0 0 1 (33%)
BAV balloon valvuloplasty, BMI body mass index, CABG coronary artery bypass grafting, CVD cerebrovascular disease,
ECMO extracorporeal membrane oxygenation, eGFR estimated glomerular ﬁltration rate, LVEF left ventricular ejection
fraction, MI myocardial infarction, PCI percutaneous coronary intervention, PVD peripheral vascular disease, SD standard
deviation
a Mean ± SD (range)
50 Cardiol Ther (2015) 4:47–58
Table 2 Procedural characteristics in patients undergoing PCI
Pre-procedural characteristics N5 45
Urgency of procedure
Elective PCI (Angina) 17 (38%)
Urgent PCI (NSTEMI) 28 (62%)
Cardiogenic shock (NSTEMI) 3 (7%)
Pulmonary oedema (NSTEMI) 2 (4%)
High-risk PCI features
Unprotected left main stem 24 (53%)
Last remaining vessel 9 (20%)
Multi-vessel 18 (40%)
Severe LV impairment (LVEF\35%) 36 (80%)
Decision for PCI
Refused CABG (MDT) 28 (62%)
Patient preference 2 (4%)
Physician’s decision (no MDT) 8 (18%)
Haemodynamic compromise (no MDT) 5 (11%)
Other 2 (4%)
Logistic Euroscore 8 ± 3 (1–15)
NWQIP PCI risk score 6 ± 11 (0.4–71)
Peri-procedural characteristics N5 45
Number of lesions treated 2.0 ± 1.0
Number of stents 2.7 ± 1.7 (1–8)
Rotational atherectomy 14 (31%)
Glycoprotein inhibitor use 1 (2%)
Complete revascularisation 45 (100%)
Impella characteristics
Successful insertion 44 (98%)
2.5L device 34 (77%)
3.8L device 10 (23%)
Removal on table 42 (95%)
CABG coronary artery bypass grafting, LVEF left ventricular ejection fraction, MDT multi-disciplinary team, NSTEMI
non-ST elevation myocardial infarction, NWQIP north west quality improvement programme, PCI percutaneous coronary
intervention
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28 (62%) patients had a non-ST elevation
myocardial infarction (NSTEMI) and
underwent in patient revascularisation. These
28 patients—11 elective and 17 urgent—were
discussed by the heart MDT and refused CABG
due to co-morbidities. Two of the 17 urgent
patients expressed a clear preference for PCI
over CABG. Five other patients developed
ischaemic haemodynamic compromise, three
of which had cardiogenic shock and two
pulmonary oedema, while awaiting MDT
discussion. One patient with severe LV
dysfunction due to non-compaction and a
single coronary ostium had Impella-assisted
PCI to a severely diseased right coronary artery
(RCA).
Finally, 18 patients (40%) underwent multi-
vessel PCI; 117 stents (mean ± SD 2.7 ± 1.7
lesions) were used to treat 89 lesions
(mean ± SD 2.0 ± 1.0 stents) in 45 patients.
Rotational atherectomy was carried out in 14
(31%) patients. Complete revascularisation,
defined as revascularisation of all intended
targets was achieved in all patients.
Impella for Balloon Aortic Valvuloplasty
One patient with severe AS and intractable
cardiogenic shock underwent successful bail-
out balloon valvuloplasty with Impella (3.8L)
support. The patient tolerated the procedure
well with a favourable haemodynamic response.
However, he had a suspected retroperitoneal
haematoma which prompted removal of the
device. Shortly afterwards, the patient
succumbed to pulmonary oedema and
cardiogenic shock.
Impella as a Bridge to Transplant
Three patients had Impella as a bridge to cardiac
transplantation. Two of these patients had
acute cardiogenic shock following ST-elevated
myocardial infarction (STEMI), despite
successful primary angioplasty and
conventional management including IABP.
One patient had a 2.5L Impella implanted via
the femoral approach, which allowed sufficient
haemodynamic recovery and made the patient
suitable for transplantation with an excellent
outcome. The other patient had a 5L Impella
(21F) inserted via surgical subclavian access, but
unfortunately, passed away due to gastro-
intestinal bleeding and multiple organ system
failure—complications unrelated to Impella.
The third patient with acute decompensated
heart (and renal) failure due to dilated
cardiomyopathy had a 2.5L Impella implanted
femorally but needed early extracorporeal
membrane oxygenation (ECMO) due to
insufficient haemodynamic response; he
eventually underwent successful cardiac and
renal transplantation.
Outcomes
The 30-day outcomes are shown in Table 3. In-
hospital death occurred in 10 patients (20%).
One patient in whom Impella could not be
implanted due to vessel tortuosity underwent
high-risk PCI but died due to ischaemic
cardiogenic shock immediately following the
procedure. Two further patients in this group
died due to cardiogenic shock, while one died of
pre-existing severe sepsis, having also had a
stroke with a dense neurodeficit in the setting of
significant bilateral carotid artery stenoses. Two
patients were given blood transfusions but only
as an aid to clinical recovery in the setting of
pre-existing anaemia with no evidence of
bleeding or a fall in haemoglobin levels. One
patient who underwent rotablation and PCI to
an unprotected left main stem and left-anterior
descending (LAD) artery unfortunately
52 Cardiol Ther (2015) 4:47–58
developed coronary perforation and
tamponade. Impella provided excellent
support while this was managed and the
device was removed successfully at the end of
the procedure. The patient subsequently died
on day 2 post-PCI. Another patient who
underwent BAV had a suspected
retroperitoneal haematoma which could not
be radiologically confirmed, as he passed away
as soon as the Impella device was removed.
There were no other major vascular
complications.
Within the group of patients studied, 30-day
survival was 80% (39/49), while overall survival
after a median follow-up of 29 months (range
1–71 months) was 65% (32/49), as shown in
Fig. 1.
DISCUSSION
We have reported the first real-world experience
of the Impella percutaneous left ventricular
assist device including the 3.8L device across a
range of indications. We have demonstrated its
safety, feasibility and efficacy in high-risk PCI,
to support BAV and as a bridge to
transplantation in acute decompensated heart
failure.
The BCIS-1 investigators reported no
reduction in 30-day major adverse cardiac
events (MACE) with the use of IABP
prophylactically in elective high-risk PCI [5].
However, on longer follow-up of 5 years, there
was a statistically significant reduction in all––
cause mortality in the IABP group [25],
although the mechanism of this benefit is
unclear. While the role of IABP in the elective
setting remains controversial, current
guidelines [30] and recent trials [6] have also
questioned the efficacy of IABP in cardiogenic
shock complicating acute myocardial
infarction.
The Impella ventricular assist device (VAD)
system, however, has been shown to provide
superior haemodynamic support than IABP [16,
Table 3 Outcomes
Outcomes Total (N5 49) High-risk PCI (N5 45) BAV (N5 1) Transplant (N5 3)
30-day mortality 10 (20%) 8 (18%) 1 (100%) 1 (33%)
Blood transfusion 3 (6%) 2 (5%) 0 1 (33%)
Vascular complications 1 (2%) 0 1 (100%) 0
Stroke 1 (2%) 1 (2%) 0 0
PMI 1 (2%) 1 (2%) 1 (100%) 0
Hospital stay (days) 5 ± 6 (1–22) 5 ± 6 (1–22) – –
BAV balloon aortic valvuloplasty, PCI percutaneous coronary intervention, PMI peri-procedural myocardial infarction
Fig. 1 Kaplan–Meier Curve showing survival over a
median follow-up period of 29 months (range 1–71)
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17]. The randomised PROTECT-II study [16]
demonstrated that in the setting of high-risk
elective PCI, the Impella device not only
provided superior haemodynamic support
than IABP, but also resulted in a statistically
significant 22% reduction in major adverse
events at 90 days largely driven by a reduction
in repeat revascularisation. Impella facilitated
more aggressive and complete revascularisation
with a higher use of rotational atherectomy
(14% vs. 9%). Similarly, we have also shown a
high proportion of rotational atherectomy
(31%) in our high-risk PCI cohort.
At present, there is no agreed definition of
what constitutes a high-risk PCI, although large
registries such as Europella [15] and USpella [1]
have included patients undergoing PCI to
unprotected left main stem, PCI to the last
remaining vessel and multivessel PCI in the
context of impaired left ventricular function.
Patients not suitable for CABG due to high risk
are increasingly undergoing PCI which has been
shown to be a safe and feasible strategy in these
patients [1]. 62% of our patients were discussed
by the MDT and were deemed to be at too high
risk for CABG due to co-morbidities.
Several risk scoring models such as the Mayo
PCI risk score have been developed to anticipate
the in-hospital major event rate in PCI. We have
used the North West Quality Improvement
Programme (NWQIP) scoring system, which
had been standardised to a UK population and
validated against the established international
risk models [31]. Population-based risk models,
however, may not capture all the high-risk
characteristics of an individual patient, and
the definition of high-risk PCI and the need
for mechanical LV support remains the
discretion of the operator. Indeed our mean
NWQIP predicted major event rate was 6 ± 11%
(range 0.4–71), which is comparable to the
mean Mayo PCI score in the PROTECT II trial
(8.8 ± 3.4% in the Impella group) [16],
although our in-hospital mortality was
significantly higher at 20%.
The overall 30-day major arrhythmic events
(MAE) rate in the USpella registry was 8% with
4% in-hospital mortality [1]. In the Europella
registry, 30-day mortality was 5.5% with a
30-day MAE rate of 12.3% (including major
vascular complications) [15]. Our in-hospital
mortality and MAE of 20% is substantially
higher than both these registries. This may
either be a reflection of smaller patient numbers
in this study, or the higher-risk profile of the
population, as discussed earlier. Indeed in the
smaller cohort of the Protect I trial (N = 20), the
30-day MAE rate was 20% [32], while in the
larger PROTECT II trial (N = 225) it was 7% [16].
Interestingly, we report only one major
vascular complication in our cohort as
compared to 4% in USpella and 5.5% in the
Europella registry. While this could be a
reflection of smaller patient numbers, it also
suggests increasing experience with larger
arterial access in the era of percutaneous
valvular interventions (TAVI) and the use of
newer techniques such as micropuncture and
pre-closure with percutaneous suture devices.
This is important in a cohort of patients who
can ill-afford any further haemodynamic
setbacks.
In this cohort, 52% had PCI to unprotected
left main stem, 40% underwent multi-vessel PCI
and 20% had PCI to the last remaining vessel—
essentially comparable to the USpella [1] and
Europella [15] registries. However, our patients
were older (mean age 75 vs. 70 years in the
USpella and Europella registries) and had a
greater incidence of severe LV impairment
(80% vs. 69%). Although the distribution of
elective and urgent PCI was comparable to the
USpella registry (the Europella registry only
included elective cases), we have used Impella
54 Cardiol Ther (2015) 4:47–58
in 3 patients with cardiogenic shock, 2 with
ischaemic pulmonary oedema and,
importantly, in 5 patients with coexisting
severe AS; patients with these conditions were
not included in the larger registries. Overall, our
patients were a substantially higher-risk cohort
when compared to these registries. This reflects
a growing confidence in the use of Impella and
its expanding indications in acute cardiac care.
Impella in Aortic Stenosis
Severe AS is reported to be a contraindication to
Impella use due to theoretical concerns of either
reducing effective valve orifice or inducing
aortic incompetence. However, with increasing
experience there have been anecdotal reports
[33, 34] and a recent series [35] describing the
use of Impella in this setting. The use of Impella
in our patients with severe AS is an example of
the expanding indication for this device. The
methods used for implanting the device in these
patients have been described by our group in a
previous report [27]. One patient with severe AS
and LV dysfunction underwent emergency BAV
with Impella support for intractable cardiogenic
shock. The rapid deterioration and death that
followed removal of the device in this patient
for suspected retroperitoneal bleeding
highlighted the significant haemodynamic
benefit provided by Impella.
Transplantation
Impella was used with success in one patient
with acute post-infarct cardiogenic shock as a
bridge to transplantation. There are anecdotal
reports of the use of Impella in similar
situations with both the 2.5L and 5L device,
and also in transplanted hearts for acute
rejection [21, 22]. A recent series [36] has also
reported the use of 5L Impella support in 9
patients with cardiogenic shock due to end-
stage ischaemic cardiomyopathy (3 patients)
and post-ST elevation myocardial infarction (6
patients). This less invasive percutaneous VAD
is therefore, a useful additional tool in advanced
heart failure management.
We have described the use of the Impella CP
3.8L device in 11 patients—10 for PCI and one
BAV. To our knowledge, this is the first series
reporting the use of the 3.8L device which has
only recently received Conformite´ Europe´enne
(CE) marking. Notably, despite the larger lumen
vascular access (14F vs. 13F for 2.5L), there was
no increase in the incidence of vascular
complications, and the haemodynamic
support was reliable and superior to that
provided by the 2.5L device.
We have confirmed that the indications for
the Impella device are expanding and that it can
be used in acutely unwell patients with a high
degree of success. The main limitations of the
Impella device include the requirement for large
lumen vascular access and closure, and the
significantly higher cost of the device as
compared to mechanical support using IABP.
A recent study has also confirmed cost-
effectiveness of Impella [37] compared with
IABP, an issue which is crucial in the current
economic environment. Moreover, the 2014
European Society of Cardiology guidelines on
myocardial revascularisation no longer
recommend routine use of IABP in cardiogenic
shock, complicating myocardial infarction
(class III recommendation). However,
mechanical support using devices such as
Impella may now be considered for short-term
support (class IIb recommendation) in this
setting [38].
The main limitation of our study is its
retrospective nature. No comparison with IABP
use was attempted, as IABP was used in milder
degrees of circulatory disturbance whereas
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Impella was often used as a last resort. This
retrospective analysis provides an insight into
‘‘real-world’’ experience with Impella.
CONCLUSION
We have demonstrated its feasibility and safety
in a cohort of higher risk patients with extended
and novel indications, and reported for the first
time globally the feasibility and safety of the
3.8L device. With increasing experience in the
use of Impella, the device may be used to
provide invaluable support to increasingly
complex patients who would, in turn, have
the largest benefit. This could be a subject of
future larger studies.
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